Clinical Study Demonstrates Superior Bioavailability of Jarrow's Proprietary QH-abso...(href ); target _blank title Kaneka Co...),Health

Date:6/13/2009

href );" target="_blank" title="Kaneka Corporation">Kaneka Corporation, the world's largest manufacturer of CoQ10. The Kaneka production process yields Co-Q10 of the highest purity and potency available.

Jarrow Formulas® is a direct contributor to research on CoQ10. It has funded several clinical trials on the nutrient, as well as acts as a sponsor for the international society that promotes research and education regarding coenzyme Q10.

The suggested retail price (SRP) for Jarrow Formulas®' QH-absorb® products are as follows:

QH-absorb®, 60 softgels (30 mg): $21.95 QH-absorb®, 60 softgels (100 mg): $55.95 QH-absorb®, 30 softgels (200 mg): $49.95

Jarrow Formulas® is a nutritional supplement formulator and marketer founded in 1977 and incorporated in 1988. The company markets its products throughout the world, including the United States, Mexico, Canada, England, France, Japan, Singapore, China, Taiwan, Israel, Kuwait, Azerbaijan and other countries. The company offers a complete line of nutritional products that includes vitamins, minerals, specialty antioxidants, probiotics, amino acids, standardized herbal concentrates and enzymes. Jarrow Formulas, Inc. is active in regulatory affairs, helping to maintain Americans' rights to free access to dietary supplements. Its products are manufactured by Jarrow Industries Incorpora
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS
2. Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawal
3. Clinical Innovations Introduces New Circumcision Device
4. New Directions in Angioedema: A Focus on Etiologies and Clinical Approach
5. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
11. Ross University School of Medicine Expands Clinical Rotations in Miami